Smith Anglin Financial’s Cognition Therapeutics CGTX Stock Holding History

Smith Anglin Financial’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$3.72K	Hold	12,000	–	–	﹤0.01%	209
2025 Q1	$5.05K	Hold	12,000	–	–	﹤0.01%	213
2024 Q4	$8.42K	Hold	12,000	–	–	﹤0.01%	213
2024 Q3	$5.62K	Hold	12,000	–	–	﹤0.01%	207
2024 Q2	$19.9K	Hold	12,000	–	–	﹤0.01%	195
2024 Q1	$21.8K	Hold	12,000	–	–	﹤0.01%	198
2023 Q4	$22.2K	Buy	+12,000	New	+$15.9K	﹤0.01%	182

Other funds holding CGTX

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

AFG

American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return

Smith Anglin Financial's CGTX Position: Q2 2025 in Review

Smith Anglin Financial held its Cognition Therapeutics (CGTX) position steady in Q2 2025 at 12,000 shares worth $3.72K. The position accounts for ﹤0.01% of the portfolio, ranked #209.

Smith Anglin Financial first reported a position in CGTX in Q4 2023 and has held it in 7 quarters since. The position peaked at $22.2K in Q4 2023. 48 funds tracked by Wall St. Rank hold CGTX as of Q2 2025.

Smith Anglin Financial held 12,000 shares of Cognition Therapeutics worth $3.72K as of Q2 2025.
Smith Anglin Financial left its Cognition Therapeutics share count unchanged in Q2 2025.
Cognition Therapeutics made up ﹤0.01% of Smith Anglin Financial's portfolio in Q2 2025, its #209 holding.
Smith Anglin Financial first reported a position in Cognition Therapeutics in Q4 2023 and has held it in 7 quarters since.
Smith Anglin Financial's Cognition Therapeutics position peaked at $22.2K in Q4 2023.
48 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2025.

Based on Smith Anglin Financial's 13F filing for Q2 2025, filed 17 Jul 2025.